ANJALI SRIVASTAVA

Ms. ANJALI SRIVASTAVA

Senior Research Fellow
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
Ana Karina Aranda-RiveraAna Karina Aranda-Rivera
Ana Karina Aranda-Rivera
ASANJALI SRIVASTAVA
ANJALI SRIVASTAVA
Alfredo Cruz GregorioAlfredo Cruz Gregorio
Alfredo Cruz Gregorio
José Pedraza-ChaverriJosé Pedraza-Chaverri
José Pedraza-Chaverri
Shrikant R. MulayShrikant R. Mulay
Shrikant R. Mulay
ASAlexandra Scholze
Alexandra Scholze
Inflammasomes are multiprotein complexes with an important role in the innate immune response. Canonical activation of inflammasomes results in caspase-1 activation and maturation of cytokines interleukin-1β and -18. These cytokines can elicit their effects through receptor activation, both locally within a certain tissue and systemically. Animal models of kidney diseases have shown inflammasome involvement in inflammation, pyroptosis and fibrosis. In particular, the inflammasome component nucleotide-binding domain-like receptor family pyrin domain containing 3 (NLRP3) and related canonical mechanisms have been investigated. However, it has become increasingly clear that other inflammasome components are also of importance in kidney disease. Moreover, it is becoming obvious that the range of molecular interaction partners of inflammasome components in kidney diseases is wide. This review provides insights into these current areas of research, with special emphasis on the interaction of inflammasome components and redox signalling, endoplasmic reticulum stress, and mitochondrial function. We present our findings separately for acute kidney injury and chronic kidney disease. As we strictly divided the results into preclinical and clinical data, this review enables comparison of results from those complementary research specialities. However, it also reveals that knowledge gaps exist, especially in clinical acute kidney injury inflammasome research. Furthermore, patient comorbidities and treatments seem important drivers of inflammasome component alterations in human kidney disease.

1 April 2002 in Environmental Monitoring and Assessment
Verified
Journal Article
Closed access
PDF file
ASANJALI SRIVASTAVA
ANJALI SRIVASTAVA
Rakesh KumarRakesh Kumar
Rakesh Kumar

3 January 2015 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
SASrivandana Akshintala
Srivandana Akshintala
LMLeigh Marcus
Leigh Marcus
KWKatherine E. Warren
Katherine E. Warren
RMRobert F. Murphy
Robert F. Murphy
TSTristan M. Sissung
Tristan M. Sissung
BWBrigitte C. Widemann
Brigitte C. Widemann
Background Based on pre‐clinical and clinical activity in adult refractory tumors, and absence of significant neuro‐, nephro‐, or oto‐toxicity, we conducted a pediatric phase 1 trial to determine the toxicities, maximum tolerated dose (MTD), and pharmacokinetics of satraplatin, an oral platinum analogue, in children and young adults with refractory solid tumors. Procedure Satraplatin was administered orally once daily on days 1–5 of a 28‐day cycle at dose level (DL) 1 (60 mg/m2/dose), and DL2 (80 mg/m2/dose). Toxicities, responses, satraplatin pharmacokinetics, and pharmacogenomic expression of specific DNA repair genes were evaluated. Results Nine patients received 1–15 cycles (median = 2). The MTD was exceeded at DL2 with delayed prolonged myelosuppression as dose‐limiting toxicity (DLT) in 2/4 patients. At DL1, 0/5 patients had DLTs. Common non‐DLTs included myelosuppression, gastrointestinal toxicities, fatigue, headache, liver enzyme elevation, and electrolyte abnormalities. No significant neuro‐, nephro‐, or oto‐toxicity was observed. No objective responses were observed but 2 patients experienced prolonged disease stabilization (­­­6–15 cycles). Satraplatin exposure (day 1 plasma ultrafiltrate area under the curve) was similar at DL1 and DL2. A strong correlation between estimated creatinine clearance and satraplatin pharmacokinetic parameters (clearance, area under the curve, and peak concentration) was observed. Conclusions The MTD of oral satraplatin in children with solid tumors was 60 mg/m2/dose daily ×5 days every 28 days, which is lower than the adult recommended dose of 80–120 mg/m2/dose. The toxicity profile was similar to adults and delayed myelosuppression was the DLT. No significant neuro‐, nephro‐ or oto‐toxicities were observed. Pediatr Blood Cancer 2015;62:603–610.

3 January 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
ASANJALI SRIVASTAVA
ANJALI SRIVASTAVA
OSOmprakash Shete
Omprakash Shete
AGAnnu Gulia
Annu Gulia
SASumit Aggarwal
Sumit Aggarwal
TGTarini Ghosh
Tarini Ghosh
Sachit AnandSachit Anand
Sachit Anand
Background: The complex interaction between the gut and urinary microbiota underscores the importance of understanding microbial dysbiosis in pediatric urinary tract infection (UTI). However, the literature on the gut–urinary axis in pediatric UTIs is limited. This systematic review aims to summarize the current literature on the roles of gut and urinary dysbiosis in pediatric UTIs. Methods: This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search was performed across four databases, including PubMed, Web of Science, Scopus, and EMBASE. All studies published between January 2003 and December 2023 utilizing 16S rRNA sequencing to profile the gut or urinary microbiome in children with UTIs were included. Heat map visualization was used to compare microbial profiles between UTI and control cohorts. The methodological quality assessment was performed using the Newcastle–Ottawa scale (NOS). Results: Eight studies were included in this review. While five studies compared the microbiota signatures between patients and controls, three studies focused solely on the UTI cohort. Also, the gut and urinary microbiome profiles were investigated by four studies each. The consistent loss of microbiome alpha-diversity with an enrichment of specific putative pathobiont microbes was observed among the included studies. Escherichia coli consistently emerged as the predominant uropathogen in pediatric UTIs. In addition to this, Escherichia fergusonii, Klebsiella pneumoniae, and Shigella flexneri were isolated in the urine of children with UTIs, and enrichment of Escherichia, Enterococcus, Enterobacter, and Bacillus was demonstrated in the gut microbiota of UTI patients. On the contrary, certain genera, such as Achromobacter, Alistipes, Ezakiella, Finegoldia, Haemophilus, Lactobacillus, Massilia, Prevotella, Bacteroides, and Ureaplasma, were isolated from the controls, predominantly in the fecal samples. The methodological quality of the included studies was variable, with total scores (NOS) ranging from 5 to 8. Conclusions: The enrichment of specific pathobionts, such as Escherichia coli, in the fecal or urinary samples of the UTI cohort, along with the presence of core microbiome-associated genera in the non-UTI population, underscores the critical role of the gut–urinary axis in pediatric UTI pathogenesis. These findings highlight the potential for microbiome-based strategies in pediatric UTIs. Further studies with larger cohorts, standardized healthy controls, and longitudinal profiling are essential to validate these observations and translate them into clinical practice.


27 March 2025 in Research Square
Verified
Preprint
Open access
PDF file
ASANJALI SRIVASTAVA
ANJALI SRIVASTAVA
Sachit AnandSachit Anand
Sachit Anand
HKHimalaya Kumar
Himalaya Kumar
JMJitendra Kumar Meena
Jitendra Kumar Meena
AVAjay Verma
Ajay Verma
PHPankaj Hari
Pankaj Hari
Background Urinary biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and Renalase hold promise for assessing kidney health, yet their role in the pediatric neurogenic bladder (NB) remains unclear. This study evaluates their clinical utility in detecting kidney dysfunction and their association with disease severity. Methods A cross-sectional study included 44 NB patients and 45 age- and gender-matched healthy children (reference group). Urinary NGAL and Renalase levels were measured using ELISA. NB patients were categorized based on glomerular filtration rate (GFR) and kidney scarring. Biomarker levels were compared using the Mann-Whitney U test, and their correlations with functional parameters (DTPA, DMSA) were assessed using Spearman’s correlation. Results Urinary NGAL and Renalase levels were significantly higher in NB patients than in the reference group (NGAL: 31.86 vs. 23.40 pg/mg creatinine, p = 0.0345; Renalase: 2.75 vs. 1.76 ng/mg creatinine, p = 0.0493). NB patients with GFR < 60 mL/min/1.73 m² or kidney scarring had elevated NGAL (46.90 vs. 26.76 pg/mg creatinine, p = 0.0406) and Renalase (3.76 vs. 1.82 ng/mg creatinine, p = 0.0050). Both biomarkers correlated inversely with GFR (NGAL: r = -0.3344, p = 0.0326; Renalase: r = -0.4054, p = 0.0085) and increased with kidney scarring, suggesting their potential role in assessing kidney injury severity. Conclusions Urinary NGAL and Renalase are elevated in pediatric NB patients, particularly in those with kidney dysfunction, and correlate with GFR and kidney scarring. These findings highlight their potential as non-invasive markers for early detection and monitoring of kidney impairment in NB. Future longitudinal studies are warranted to validate their diagnostic and prognostic utility.